Management of Hepatitis C
Completed: 2002 Investigators Kelly A. Gebo, MD, MPH
Mollie W. Jenckes, MHSc, BSN
Geetanjeli Chander, MD
Michael S. Torbenson, MD
Khalil G. Ghanem, MD
H. Franklin Herlong, MD
Mark S. Sulkowski, MD
Samer S. El-Kamary, MD
Kirk A. Harris, BA
Otto C. Guedelhoefer
Eric B. Bass, MD, MPH
Questions
The following research questions were addressed: Does use of initial or serial liver biopsies improve outcomes in the management of patients with chronic Hepatitis C? How well do serologic measures of fibrosis predict the findings of liver biopsy in patients with chronic Hepatitis C? (a) What is the overall efficacy and safety of current treatment options for chronic Hepatitis C (pegylated interferon plus ribavirin, non-pegylated ribavirin, or other interferon based therapy)?(b) What is the efficacy and safety of current treatment options for chronic Hepatitis C (pegylated interferon plus ribavirin, non-pegylated interferonplus ribavirin, or other interferon based therapy) in subgroups of patients, especially those defined by the following patient characteristics: age = 18 years, Hepatitis C genotype, presence or absence of cirrhosis, minimal versus decompensated liver disease, concurrent Hepatitis B or HIV infection, non-response to initial interferon based therapy, and relapse after initial interferon based therapy. (a) What is the efficacy of using screening tests for hepatocellular carcinoma (HCC) to improve clinical outcomes in patients with chronic Hepatitis C? (b) What are the sensitivity, specificity, and predictive values of tests that could be used to screen for potentially curable hepatocellular carcinoma in patients with chronic Hepatitis C?
link to summary of report on AHRQ site link to evidence report on AHRQ site
|
